Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,688Revenue $M35,394Net Margin (%)12.0Z-Score2.3
Enterprise Value $M153,339EPS $1.7Operating Margin %15.6F-Score6
P/E(ttm))18.0Cash Flow Per Share $0Pre-tax Margin (%)12.9Higher ROA y-yY
Price/Book17.510-y EBITDA Growth Rate %3.3Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %1.5Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-22.6ROA % (ttm)6.8Higher Current Ratio y-yN
Dividend Yield %5.5Insider Buy (3m)0ROE % (ttm)47.5Less Shares Outstanding y-yY
Payout Ratio %93.0Shares Outstanding M2,402ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKHOTCHKIS & WILEY 2014-12-31 Add0.21%$41.3 - $47.14
($44.76)
$ 47.426%Add 13.04%12,213,885
GSKDodge & Cox 2014-12-31 Reduce-0.64%$41.3 - $47.14
($44.76)
$ 47.426%Reduce -37.91%23,959,301
GSKDavid Dreman 2014-12-31 Sold Out -0.01%$41.3 - $47.14
($44.77)
$ 47.426%Sold Out0
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 47.42-3%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 47.42-3%Add 36.63%3,415,717
GSKIrving Kahn 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 47.42-3%New holding, 51000 sh.51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 47.42-3%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 47.42-3%New holding, 1328 sh.1,328
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 47.42-3%Reduce -35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 47.42-12%Add 13358.6%4,949,118
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 47.42-12%Add 49.33%988,772
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 47.42-12%Add 15.52%2,500,048
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 47.42-12%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 47.42-12%Reduce -43.82%5,156,449
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 47.42-12%Add 57.21%662,150
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 47.42-12%New holding, 36773 sh.36,773
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 47.42-12%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 47.42-12%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 47.42-12%Reduce -28.91%148,800
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 47.42-9%Add 1702.13%423,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK HOTCHKIS & WILEY 2014-12-3112,213,8850.511.8+13.04%
GSK John Rogers 2014-12-311,044,9230.040.52+3.91%
GSK James Barrow 2014-12-31270,9000.010.02
GSK Irving Kahn 2014-12-3151,00000.38
GSK Jean-Marie Eveillard 2014-12-31100
GSK PRIMECAP Management 2014-12-314,873,2350.20.21-0.03%
GSK Joel Greenblatt 2014-12-3183,23300.03-0.27%
GSK NWQ Managers 2014-12-31204,6250.010.1-1.68%
GSK Charles Brandes 2014-12-313,281,7800.142-3.92%
GSK Tweedy Browne 2014-12-31134,2930.010.15-4.27%
GSK Ken Fisher 2014-12-3110,765,0040.450.95-6.3%
GSK John Hussman 2014-12-31300,0000.011.3-7.26%
GSK Dodge & Cox 2014-12-3123,959,30110.95-37.91%
GSK David Dreman 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22115.55view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14124.31view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29796.41view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12295.17view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14238.71view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12295.17view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      Bestinfond's Top 5 New Buys During Q4 Feb 03 2015 
      Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
      Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 
      Gilead Sciences Still has More Upside Jan 22 2015 
      Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
      set Jan 11 2015 
      tester Dec 18 2014 
      Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR Dec 14 2014 

      More From Our Partners
      Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015 - ZACKS

      More From Other Websites
      Interested In Pharmaceutical Stocks? Try Novartis (ADR) Feb 27 2015
      GlaxoSmithKline plc And SkyePharma PLC: A Match Made In Heaven? Feb 27 2015
      What You Should Know Before Watching Vice's Special About Curing Cancer Feb 26 2015
      1:06 pm GlaxoSmithKline announces that Sir Christopher Gent will step down as Chairman of GSK at the... Feb 26 2015
      Glaxo Chief Witty’s Compensation Cut 46% as Profit Declined Feb 26 2015
      GlaxoSmithKline plc announces changes to its Board Feb 26 2015
      Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015
      GSK to be No. 1 vaccine producer when it completes $25B asset swap with Novartis next week Feb 25 2015
      GSK set to complete $20 billion Novartis asset swap next week Feb 25 2015
      GSK set to complete 13 billion pounds Novartis asset swap next week Feb 25 2015
      GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
      GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
      Update on three-part transaction with Novartis Feb 25 2015
      Can Isis Pharmaceuticals (ISIS) Beat Earnings this Season? - Analyst Blog Feb 25 2015
      [video]GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall Feb 25 2015
      Nonprescription diet pill alli back in stores after recall Feb 25 2015
      The Benefits Of Investing In GlaxoSmithKline plc Feb 25 2015
      Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That Feb 24 2015
      In The Book Of Life, A Second Map Is Established Feb 24 2015
      Biotech battles 'Superbug' Feb 23 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK